Business Context and Reporting Period
Company: Smith & Nephew plc (LSE: SN, NYSE: SNN)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: October 16, 2025
Reporting Period: This filing announces the timing of the Third Quarter 2025 Trading Report, covering the period ended September 27, 2025. The actual financial results are scheduled for release on November 6, 2025.
Business Overview: A global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue. The company operates three business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It employs approximately 17,000 people across more than 100 countries.
Key Financial Metrics
Current Period Data: The filing text does not provide specific financial values (revenue, profit, cash flow, margins, debt, or liquidity) for the third quarter of 2025. These figures are pending the November 6, 2025 announcement.
Historical Context: The company generated annual sales of $5.8 billion in 2024.
Material Changes
No material changes to financial performance or operations are detailed in this filing, as it serves solely as a notice of the upcoming trading report release. No comparative data for the prior period is included in this document.
Guidance, Outlook, and Risks
Outlook: The filing contains forward-looking statements regarding expected revenue growth and trading profit margins but does not provide specific numerical guidance in this text.
Risks and Contingencies: The company highlights numerous factors that could cause actual results to differ from expectations, including:
- Conflicts in Europe and the Middle East.
- Economic and financial conditions affecting healthcare providers and payers.
- Regulatory approvals, reimbursement decisions, and government actions.
- Product defects, recalls, or quality management system failures.
- Supply chain disruptions and cybersecurity risks.
- Foreign exchange volatility and changes in taxation regulations.
- Competition for qualified personnel and strategic integration risks from acquisitions.
Investor Verification Checklist
- Verify the release of the Third Quarter 2025 Trading Report on November 6, 2025, at 7:00 am GMT.
- Confirm the details of the financial analyst conference call scheduled for 8:30 am GMT on November 6, 2025.
- Review the upcoming report for specific revenue, profit, and margin figures to compare against the 2024 annual sales of $5.8 billion.
- Monitor updates on geopolitical conflicts in Europe and the Middle East for potential supply chain or market impact.
- Check for any new regulatory or reimbursement decisions affecting the Orthopaedics, Sports Medicine & ENT, or Advanced Wound Management units.